iDEL Therapeutics Overview

  • Year Founded
  • 2025

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $10.5M

  • Investors
  • 4

iDEL Therapeutics General Information

Description

Developer of a tumor-targeted intracellular delivery system intended to transport therapeutic payloads directly into the cytosol of cancer cells. The company's platform uses a synthetic shuttle mechanism that enables pan-cancer cellular uptake, high intracellular drug exposure, sustained tumor retention, compatibility with small and large molecules, including nanobody-based and cytotoxic payloads, and evasion of endosomal trapping, enabling oncology developers to access historically unreachable intracellular targets and broaden therapeutic application across diverse cancer types.

Contact Information

Website
www.idel-tx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Otto-Hahn-Straße 15
  • 44227 Dortmund
  • Germany
+49 0231
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Therapeutic Devices
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Otto-Hahn-Straße 15
  • 44227 Dortmund
  • Germany
+49 0231

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

iDEL Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 17-Mar-2026 $10.5M Completed Pre-Clinical Trials
To view iDEL Therapeutics’s complete valuation and funding history, request access »

iDEL Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
BiomedVC Venture Capital Minority
Gründerfonds Ruhr Venture Capital Minority
Khanu Management Venture Capital Minority
NRW BANK Investment Bank Minority
To view iDEL Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

iDEL Therapeutics FAQs

  • When was iDEL Therapeutics founded?

    iDEL Therapeutics was founded in 2025.

  • Where is iDEL Therapeutics headquartered?

    iDEL Therapeutics is headquartered in Dortmund, Germany.

  • What industry is iDEL Therapeutics in?

    iDEL Therapeutics’s primary industry is Drug Delivery.

  • Is iDEL Therapeutics a private or public company?

    iDEL Therapeutics is a Private company.

  • What is iDEL Therapeutics’s current revenue?

    The current revenue for iDEL Therapeutics is .

  • How much funding has iDEL Therapeutics raised over time?

    iDEL Therapeutics has raised $10.5M.

  • Who are iDEL Therapeutics’s investors?

    BiomedVC, Gründerfonds Ruhr, Khanu Management, and NRW BANK have invested in iDEL Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process